1185878-98-1

1185878-98-1 structure

Name: Pentoxifylline-d6
Chemical Name: 1-(5-oxohexyl)-3,7-bis(trideuteriomethyl)purine-2,6-dione
CAS Number: 1185878-98-1
Molecular Formula: C₁₃H₁₂D₆N₄O₃
Molecular Weight: 284.34400
Catalog: Signaling Pathways Anti-infection HIV
Create Date: 2016-10-31 19:19:33
Modify Date: 2024-01-09 19:21:02
Pentoxifylline-d6 (BL-191-d6) is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].

Name	1-(5-oxohexyl)-3,7-bis(trideuteriomethyl)purine-2,6-dione
Synonyms	Oxpentifylline-d6 Vazofirin-d6 Pentoxifylline-d6 3,7-di(methyl-d3)-1-(5-oxohexyl)-1H-purine-2,6(3H,7H)-dione 1-(5-Oxohexyl)-3,7-(dimethyl-d6)xanthine-d6 3,7-Dihydro-3,7-(dimethyl-d6)-1-(5-oxohexyl)-1H-purine-2,6-dione Trental-d6 1-(5-Oxohexyl)theobromine-d6

Description	Pentoxifylline-d6 (BL-191-d6) is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].
Related Catalog	Research Areas >> Cancer Research Areas >> Cardiovascular Disease Signaling Pathways >> Anti-infection >> HIV Signaling Pathways >> Metabolic Enzyme/Protease >> Phosphodiesterase (PDE) Signaling Pathways >> Autophagy >> Autophagy
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Iffat Hassan, et al. Pentoxifylline and its applications in dermatology. Indian Dermatol Online J. 2014 Oct-Dec; 5(4): 510–516. [3]. A Ward, et al. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs. 1987 Jul;34(1):50-97. [4]. Yessica Cristina Castellanos-Esparza, et al. Synergistic promoting effects of pentoxifylline and simvastatin on the apoptosis of triple-negative MDA-MB-231 breast cancer cells. Int J Oncol. 2018 Apr;52(4):1246-1254. [5]. Shabnam Movassaghi, et al. Effect of Pentoxifylline on Ischemia- induced Brain Damage and Spatial Memory Impairment in Rat. Iran J Basic Med Sci. 2012 Sep-Oct; 15(5): 1083-1090.

Molecular Formula	C₁₃H₁₂D₆N₄O₃
Molecular Weight	284.34400
Exact Mass	284.17600
PSA	78.89000
LogP	0.19300
Storage condition	2-8°C

10226-30-9

117490-40-1

~15%

1185878-98-1

Literature: US2009/239886 A1, ; Page/Page column 27-28 ; US 20090239886 A1

69-89-6

1185878-98-1

Literature: WO2011/28835 A1, ;

18641-05-9

1185878-98-1

Literature: WO2011/28835 A1, ;

Precursor 4
10226-30-9 117490-40-1 69-89-6 18641-05-9
DownStream 0

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

1185878-98-1	1185995-26-9
6493-05-6	130007-50-0
1246815-96-2	1328934-40-2
1346603-27-7	203645-59-4
16585-35-6	1024922-02-8
2044797-24-0	2324577-16-2
1856269-26-5	1856049-31-4
1856024-49-1	13618-81-0
2090077-56-6	2227790-43-2
2060033-15-8	2060043-07-2